[Evaluation of prevalence of delta 32 mutation in CCR5 gene in breast cancer patients in Rafsanjan city]

ABSTRACT

Chemokines and their receptors are expressed in different types of malignancies. CC chemokines MIP-1alpha [CCL3], MIP-1beta [CCL4] and RANTES [CCL5] is believed to be anti-tumor and also aid to the metastasis in tumor microenvironment. CCR2 and CCR5 are special G-protein receptors for these chemokines. Due to the important role of CCR5 chemokine receptor in tumor biology, this project is designed to examine delta 32 mutation in CCR5 gene regards breast cancer. This experimental study was performed during 2007-8 on delta healthy adults and 36 breast cancer patients by Gap-PCR. The demographic information also was collected by questionner and t-test Chi-square was used for statistical analysis of data. Our results showed that none of breast cancer patients had CCR5-delta 32 mutation while 3 [3%] cases of controls had heterozygotic form of this mutation. Our results showed that there is not any CCR5-delta 32 mutation in patients. Therefore, it appears that this mutation don't play any role in breast cancer